Medartis Holding AG (SIX: MED) announced that shareholders approved all substantive proposals of the Board of Directors with majorities exceeding 90.9% at the company's Annual General Meeting held on April 23, 2026, in Basel. The strong shareholder turnout, with 77.4% of total share capital represented, underscores investor confidence in the medical device manufacturer's direction.
All seven incumbent board members standing for re-election received resounding endorsement, each securing more than 93.8% support from represented votes. Yang Xu was newly elected to the Board of Directors with 99.7% approval and will join the Finance and Audit Committee, bringing fresh expertise to the board's oversight of financial matters.
Shareholders granted discharge to board members for their governance during the 2025 term and approved the proposed maximum total remuneration for both the Board of Directors and the Executive Management Board, including fixed and variable components. The 2025 management report and annual financial statements received nearly unanimous approval at 99.99%, while the remuneration report was approved by 91.0% in a consultative vote. Additionally, the sustainability report garnered strong endorsement from 99.2% of represented shares, confirming Medartis' commitment to transparent ESG practices.
Chairman Marco Gadola will continue to lead the board. Jennifer Dean, after two years with Medartis, decided not to stand for re-election. The assembly also confirmed Damien Tappy and Marco Gadola as members of the Human Resources and Compensation Committee, ensuring continuity in oversight of the company's human capital strategy.
The composition of the Board of Directors remains robust, with members including Marco Gadola (Chairman), Dr. h.c. Thomas Straumann (Vice Chairman), Willi Miesch, Damien Tappy, Nadia Tarolli Schmidt, Ciro Roemer, Martha Shadan, and newly elected Yang Xu. Committee assignments were also confirmed, with Nadia Tarolli Schmidt chairing the Finance and Audit Committee, Damien Tappy chairing the Human Resources and Compensation Committee, and Willi Miesch chairing the Strategy and Innovation Committee.
Shareholders also confirmed the re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors. For a detailed listing of all resolutions, please visit this link.
Medartis also announced upcoming investor events: an Investor Visitor Day in Basel on June 4, 2026, held on the fringes of the FESSH Hand Surgery Congress, and the first-half 2026 results publication on August 18, 2026, followed by an analyst and media briefing. The next Annual General Meeting is scheduled for April 22, 2027, at the company's headquarters in Basel.
The strong shareholder support at this year's AGM signals confidence in Medartis' strategic direction and governance, which is crucial as the company continues to expand its presence in the global orthopedic device market. With manufacturing sites in Switzerland, the United States, Brazil, and France, and products offered in over 60 countries, Medartis remains a key player in surgical fixation and joint replacement.
